SecBot SecBot
PRESS-RELEASE ·Filed Jun 12, 2026

IRON

Disc Medicine Inc
BULLISH
Impact 8/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Traders should monitor APOLLO Phase 3 top-line results in Q4 2026 as the single most important binary catalyst, success would confirm the CRL-response path and likely drive a >8-15% rally for this early-stage biotech. The RALLY-MF data strengthen the DISC-0974 profile ahead of End-of-Phase 2 meetings, supporting a second pivotal program. DISC-3405 initial data in Q4 adds further optionality.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$67.99
T+0 close · Jun 12, 2026 · via day close
Latest settled
+13.02%
T+60 · $76.84
Vs SPY
+9.75%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 12 $67.99entry
  2. T+1 · 5mo ago +3.09%α +1.33% · $70.09
  3. T+5 · 5mo ago +4.12%α +3.45% · $70.79
  4. T+20 · 4mo ago +12.65%α +10.87% · $76.59
  5. T+60 · 2mo ago +13.02%α +9.75% · $76.84
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Disc Medicine announced updated Phase 2 data for DISC-0974 in myelofibrosis anemia (55% major response in non-transfusion-dependent patients, 64% transfusion independence in low-burden TD) and sustained bitopertin PPIX reductions in EPP at EHA 2026. The company confirmed a Type A meeting with FDA where APOLLO Phase 3 data, due Q4 2026, can serve as basis for a CRL response and potentially support traditional approval. Initial DISC-3405 data in polycythemia vera also expected Q4 2026.

Key Facts

  • Phase 2 RALLY-MF: 55% of nTD patients achieved hemoglobin increase ≥1.5 g/dL for ≥12 weeks (major response)
  • 64% of TD Low and 50% of TD High MF patients achieved transfusion independence over 12-16 weeks
  • 56% of JAK inhibitor-concomitant patients achieved major hematologic response across transfusion groups
  • HELIOS OLE: Sustained PPIX reductions and improved light tolerance with up to 2.5+ years bitopertin exposure
  • Type A meeting confirmed APOLLO Phase 3 readout in Q4 2026 can serve as basis for CRL response and potentially support traditional approval
  • RESTORE-PV Phase 2 initial data for DISC-3405 in polycythemia vera expected Q4 2026, third program could enter pivotal development in 2027
  • DISC-0974 well-tolerated; diarrhea was only related AE in ≥2 subjects, majority of AEs not related

Financial Impact

Disc Medicine has no revenue or earnings yet. The catalyst-rich H2 2026 hinges on APOLLO bitopertin Phase 3, which can potentially resolve the existing CRL and unlock a traditional approval for EPP (an orphan indication with no approved therapies), value-driving for a $2.6B market cap biotech entirely dependent on pipeline success.

no revenueclinical pipeline

Risk Factors

  • APOLLO Phase 3 failure would be severely bearish, bitopertin is the most advanced asset and a CRL is already outstanding; a miss could eliminate path-to-approval
  • CRL on CMC or safety/efficacy grounds if APOLLO data are not clean + additional manufacturing/resolution risk before re-submission
  • Clinical-stage biotech with no revenue, any pipeline setback (DISC-0974 regulatory delay, DISC-3405 early data miss) would erode premium valuation
  • Broader biotech sentiment or financing risk, Disc may require equity raises to fund three programs

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3311034

Track record

43 reports on IRON

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +20.07% at T+20 after the Sep 3, 2026 report. 10 of 15 went positive at some point.

Filters
  1. Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
  2. Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
  3. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  4. Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
  5. Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
  6. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
  7. Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
  8. Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
  9. Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
  10. Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
Showing 10 of 43

US Market Status

Market Closed · Opens Wed (9h 45m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 12, 2026